text: <unk>  (marketed under the trade name Glybera) is a gene therapy treatment that compensates for lipoprotein lipase deficiency (LPLD), which can cause severe pancreatitis. In July 2012, the European Medicines Agency recommended it for approval, the first recommendation for a gene therapy treatment in either Europe or the United States. The recommendation was endorsed by the European Commission in November 2012 and commercial rollout is expected in late 2013.
option_0: Alipogene tiparvovec
option_1: Fosamprenavir
option_2: Abacavir lamivudine
option_3: Telaprevir
option_4: Remdesivir
option_5: Daclatasvir
option_6: Nevirapine
option_7: Cemiplimab-rwlc